en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:inter-word"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">PSMA is known as a suitable marker for imaging and targeted therapy of malignant tumors, especially prostate cancer. While; </span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="language:en-US">¹⁷⁷</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Lu-labeled PSMA is recognized as a promising compound for the treatment of metastatic castration-resistant prostate cancer patients, deployment of radionuclides with higher beta energy, including </span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="language:en-US">¹⁸⁸</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Re, can be useful for larger-sized tumors. However, the absorbed dose of the PSMA radiolabeled compound is substantial according to the considerable accumulation in the kidney. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> In this study; the biodistribution of </span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="language:en-US">¹⁸⁸</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Re-HYNIC-PSMA was studied in Wistar rats. ANACOMP software was utilized for compartmental modeling. The human absorbed dose of this new agent was assessed according to the rats&rsquo; biodistribution data using the RADAR method. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="language:en-US"></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">The highest accumulation of activity in Wistar rats&rsquo; organs were observed in the kidney. The human organs that received the highest absorbed dose were the kidneys and bladder wall with 0.69 and 0.46 mSv/MBq, respectively.</span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> The absorbed dose of </span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="language:en-US">¹⁸⁸</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Re-PSMA-617 in critical organs is comparable to the values of </span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="language:en-US">¹⁷⁷</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Lu-PSMA-617. </span></span></span><span lang="en-US" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="language:en-US">¹⁸⁸</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Re-HYNIC-PSMA can be considered a safe compound for the treatment of PSMA expressing tumors.</span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Tahoma"><span style="font-style:italic"><span style="language:en-US"></span></span></span></span></span></span></span></span></span></div> <span style="font-size:10pt"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black">&nbsp;</span></span></span></span><br> &nbsp; Compartmental modeling, absorbed dose, PSMA, 188Re. 823 827 http://ijrr.com/browse.php?a_code=A-10-1-984&slc_lang=en&sid=1 M. Hadisi 7900319475328460022611 7900319475328460022611 No Department of Energy Engineering, Sharif University of Technology, Tehran, Iran N. Vosoughi 7900319475328460022612 7900319475328460022612 No Department of Energy Engineering, Sharif University of Technology, Tehran, Iran H. Yousefnia hyousefnia@aeoi.org.ir 7900319475328460022613 7900319475328460022613 Yes Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran A. Bahrami-Samani Bahrami-Samani 7900319475328460022614 7900319475328460022614 No Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran S. Zolghadri 7900319475328460022615 7900319475328460022615 No Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran R. Bagheri 7900319475328460022616 7900319475328460022616 No Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran